MDL Mass Tort & Class Action Monitor
Developed to serve primarily as a litigation scouting report for plaintiff and defense counsel, insurers and legal service providers, HarrisMartin’s MDL Mass Tort & Class Action Monitor covers significant new filings and decisions in the JPML, MDL and related mass tort arenas. The quick delivery of breaking news and additional features will keep you within close range of every development occurring in the high-stakes environment of mass torts litigation — where minutes can make a difference. The MDL Mass Tort & Class Action Monitor is an online-only offering that includes frequent email updates and is available at no charge to annual and event sponsors of HarrisMartin’s CLE Conferences.
SEARCH THE ARCHIVES
Issue #32, October 2019
A national trade association has asked a Massachusetts federal judge to end the state’s four-month ban on sales of all vaping products, alleging it is unconstitutional and “will irreparably destroy Massachusetts’ $331 million nicotine-vapor products industry and the livelihoods of the 2,500 workers that it employs.”
Defendant drug makers and distributors in the federal opioid MDL have moved to stay proceedings pending the 6th Circuit U.S. Court of Appeals’ ruling on the State of Ohio’s petition to stop or delay the upcoming bellwether trial.
The U.S. Judicial Panel on Multidistrict Litigation has opted to create a coordinated multidistrict litigation docket for claims pending against JUUL Labs Inc. for its electronic nicotine delivery system, sending the cases to the Northern District of California, HarrisMartin Publishing is reporting.
Johnson & Johnson has agreed to pay $10 million on the eve of the first bellwether trial in the federal opioid multidistrict litigation, resolving two Ohio counties’ claims that it grossly misrepresented the risks of long-term use of its powerful painkillers for persons with chronic pain.
Drug distributors have asked a federal appellate court to disqualify the Ohio federal judge overseeing the opioid multidistrict litigation, arguing that his statements concerning a personal objective to abate the opioid crisis via settlements is evidence of partiality.
The Food and Drug Administration and the U.S. Drug Enforcement Administration have issued joint warning letters targeting four online networks that are allegedly selling opioids illegally.
Issue #31, September 2019
Apotex Corp. has announced that it is voluntarily recalling all of its ranitidine drugs in the United States due to reports that some brand name and generic ranitidine medicines have been contaminated by a probable human carcinogen known as N-Nitrosodimethylamine (NDMA).
The Ohio federal judge overseeing the federal opioid multidistrict litigation has refused to disqualify himself, rejecting defendants’ arguments that his active participation in encouraging settlement talks is evidence that he is biased against them.
A police officer has sued six distributors of a Chinese-made vaping pen in Washington state court, alleging his use of the product caused him to develop lipoid pneumonia.
A Florida federal judge has dismissed the claims of 149 Abilify plaintiffs with prejudice on the basis that they failed to comply with orders regarding a global settlement of all cases pending on the federal multidistrict litigation docket.